L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.

@article{Young1995L7437,
  title={L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.},
  author={Steven D Young and S F Britcher and Lekhanh O Tran and Linda S. Payne and William C. Lumma and Terry A Lyle and Joel R Huff and P. S. Anderson and David B. Olsen and Steven S. Carroll},
  journal={Antimicrobial agents and chemotherapy},
  year={1995},
  volume={39 12},
  pages={2602-5}
}
The clinical benefit of the human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) is limited by the rapid selection of inhibitor-resistant viral variants. However, it may be possible to enhance the clinical utility of this inhibitor class by deriving compounds that express both high levels of antiviral activity and an augmented pharmacokinetic profile. Accordingly, we developed a new class of NNRTIs, the 1, 4-dihydro-2H-3, 1-benzoxazin-2-ones… CONTINUE READING